María Natalia Gandur Quiroga: Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991 study results.
Quoting María Natalia Gandur Quiroga on X/Twitter:
“Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991 study results, emphasising the complexities of treating metastatic hormone-sensitive prostate cancer (mHSPC). Here’s what we’ve learned:
KEYNOTE-991 Study Insights:
– Study halted: Pembro + Enza + ADT didn’t improve outcomes in mHSPC patients, escalating risks instead.
– rPFS, OS, and TT SSE outcomes were comparable between Pembro + Enza vs PBO + Enza groups.
– Significant increase in Grade ≥3 Treatment-Related Adverse Events (TRAEs) observed with the combination therapy .
This setback highlights the challenges in prostate cancer research and underscores the importance of rigorous evaluation in clinical trials. Research continues for better solutions in the fight against mHSPC.”
Source: María Natalia Gandur Quirog/Twitter.
María Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows